Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below 200 Day Moving Average of $3.29

Spero Therapeutics, Inc. (NASDAQ:SPROGet Rating) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.29 and traded as low as $1.10. Spero Therapeutics shares last traded at $1.12, with a volume of 3,788,442 shares traded.

Analysts Set New Price Targets

SPRO has been the topic of several analyst reports. Berenberg Bank lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 20th. HC Wainwright decreased their price objective on shares of Spero Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, August 15th. Finally, Cantor Fitzgerald decreased their price objective on shares of Spero Therapeutics from $27.00 to $5.00 in a report on Tuesday, May 17th.

Spero Therapeutics Trading Down 8.2 %

The stock has a market cap of $39.28 million, a P/E ratio of -0.32 and a beta of 1.87. The business’s fifty day simple moving average is $0.85 and its 200 day simple moving average is $3.29.

Institutional Trading of Spero Therapeutics

A number of hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its position in shares of Spero Therapeutics by 114.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 303,201 shares of the company’s stock valued at $225,000 after acquiring an additional 161,775 shares during the period. AQR Capital Management LLC acquired a new stake in Spero Therapeutics during the 2nd quarter worth approximately $115,000. Millennium Management LLC raised its holdings in Spero Therapeutics by 413.6% during the 2nd quarter. Millennium Management LLC now owns 314,643 shares of the company’s stock worth $233,000 after buying an additional 253,382 shares during the period. Renaissance Technologies LLC grew its stake in shares of Spero Therapeutics by 760.7% during the 2nd quarter. Renaissance Technologies LLC now owns 939,017 shares of the company’s stock worth $696,000 after acquiring an additional 829,917 shares in the last quarter. Finally, Kingsbury Capital Investment Advisors LLC bought a new position in shares of Spero Therapeutics in the second quarter valued at $45,000. 57.38% of the stock is currently owned by institutional investors and hedge funds.

About Spero Therapeutics

(Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Read More

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.